Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TPST | US
0.04
3.60%
Healthcare
Biotechnology
30/06/2024
17/10/2024
1.15
1.12
1.20
1.02
Tempest Therapeutics Inc. a clinical-stage oncology company develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495 a dual antagonist of EP2 and EP4 receptors of prostaglandin E2 which is in a Phase 1 trial to treat solid tumors; and TPST-1120 a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1 a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics Inc. is headquartered in Brisbane California.
View LessStrength based on increasing price with high volume
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
126.0%1 month
100.8%3 months
118.7%6 months
99.3%-
-
1.53
1.20
0.48
0.31
-
-
-31.25M
31.11M
31.11M
-
-
-
-
-289.26
5.12
8.91
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.67
Range1M
0.67
Range3M
1.26
Rel. volume
1.84
Price X volume
12.02M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
OKYO Pharma Limited | OKYO | Biotechnology | 1.01 | 34.17M | -3.81% | n/a | -107.88% |
OCUP | OCUP | Biotechnology | 1.27 | 33.54M | -0.78% | n/a | 0.00% |
Moolec Science SA Ordinary Shares | MLEC | Biotechnology | 0.89 | 33.34M | -3.26% | n/a | 209.19% |
Dyadic International Inc | DYAI | Biotechnology | 1.13 | 33.31M | -2.59% | n/a | 175.64% |
Acasti Pharma Inc | ACST | Biotechnology | 3.2816 | 33.28M | -2.04% | n/a | 0.00% |
Acurx Pharmaceuticals Inc. Common Stock | ACXP | Biotechnology | 2.02 | 32.82M | -1.46% | n/a | 0.00% |
Curis Inc | CRIS | Biotechnology | 5.34 | 31.93M | 0.56% | n/a | -6039.91% |
Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 2.21 | 31.73M | 10.50% | n/a | 11.72% |
Surrozen Inc. Common Stock | SRZN | Biotechnology | 9.76 | 31.29M | -7.05% | n/a | 35.73% |
ProMIS Neurosciences Inc. | PMN | Biotechnology | 1.045 | 31.23M | 0.48% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.31 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 1.53 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 118.72 | 72.92 | Riskier |
Debt to Equity | 1.20 | -1.24 | Expensive |
Debt to Assets | 0.48 | 0.25 | Expensive |
Market Cap | 31.11M | 3.78B | Emerging |